Trurapi®

Clinical Indication

INSULIN ASPART

Comments

First line cost effective choice of rapid acting insulin aspart (biosimilar).

Date of classification

December 2022

Green

Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.